chr1-182860092-G-A
Variant summary
Our verdict is Likely pathogenic. Variant got 7 ACMG points: 7P and 0B. PM2PP3_StrongPP5
The NM_001357.5(DHX9):c.1240G>A(p.Gly414Arg) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 12/21 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (no stars).
Frequency
Consequence
NM_001357.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 7 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
DHX9 | NM_001357.5 | c.1240G>A | p.Gly414Arg | missense_variant | 12/28 | ENST00000367549.4 | NP_001348.2 | |
DHX9 | NR_033302.2 | n.1509G>A | non_coding_transcript_exon_variant | 13/29 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
DHX9 | ENST00000367549.4 | c.1240G>A | p.Gly414Arg | missense_variant | 12/28 | 1 | NM_001357.5 | ENSP00000356520.3 | ||
DHX9 | ENST00000477802.1 | n.243G>A | non_coding_transcript_exon_variant | 3/3 | 2 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 30
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
DHX9-related disorder Pathogenic:1
Likely pathogenic, no assertion criteria provided | in vivo;research | Center for Medical Genetics, Keio University School of Medicine | Jul 27, 2022 | - - |
INTELLECTUAL DEVELOPMENTAL DISORDER, AUTOSOMAL DOMINANT 75 Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Oct 28, 2024 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
No publications associated with this variant yet.